We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In a matter of just a few years, “the Cloud” has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. Cloud computing is now an essential focus for software-related companies, and cloud stocks have piqued the interest of many tech-focused investors.
New technologies and changing consumer behavior have changed the shape of the technology landscape, and an industry that was once centered on the personal computer has adapted to survive in the world of mobile computing and the Cloud. The markets have been paying attention, and some of the best tech stocks have been those that are either primarily cloud-based companies, or those that have shown growth in their cloud operations.
With this in mind, we’ve highlighted three stocks that are not only showing strong cloud-related activity, but also strong fundamental metrics. Check out these three cloud stocks to buy right now:
Veeva makes cloud-based solutions for the pharmaceutical and life sciences industries. Its main offerings are presented in a software-as-a-service model and delivers industry-specific tools for CRM, content management, and many other enterprise applications. Shares of Veeva currently hold a Zacks Rank #2 (Buy).
VEEV has emerged as a hot growth and momentum stock this year, adding more than 64%—even after recent market-wide pullbacks—amid strong earnings improvements. The firm is projected to finish its current fiscal year with earnings growth of 59.1% and has a long-term expected growth rate of 19.3%. Veeva is also generating cash flow growth in excess of 86.6% currently.
2. Attunity Ltd.
Attunity is a provider of software solutions that enable access, management, sharing, and distribution of data across enterprise platforms and the Cloud. Simply put, Attunity customers have real-time access to a plethora of data and information whenever it’s needed. The firm works closely with trusted cloud leaders like AWS, Cloudera , and Microsoft (MSFT - Free Report) .
ATTU is sporting a Zacks Rank #1 (Strong Buy). The reason for this strong rank is a number of recent positive earnings estimate revisions. These bullish revisions have pushed the Zacks Consensus Estimate for ATTU’s current year EPS to 40 cents from 26 cents, while next year’s consensus has moved to 49 cents from 32 cents.
Part of this has to do with Attunity’s most recent quarter, in which the firm delivered earnings of 20 cents per share against estimates of just three cents. Now, current-year growth estimates are calling for revenue and earnings to improve by 35% and 500%, respectively.
3. Apptio, Inc.
Apptio develops cloud-based, software-as-a-service platforms for business management applications. Its enterprise-focused apps are designed to help companies assess and plan for the costs of IT services, which helps save time and money related to planning, budgeting, and forecasting. APTI currently has a Zacks Rank #2 (Buy) and an “A” grade in the Growth category of our Style Scores system.
Despite being a segment leader for years, APTI is still witnessing aggressive earnings and revenue growth. The firm’s bottom line is expected to grow 133.3% this year and revenue growth will hit 24.1%, according to our latest Zacks Consensus Estimates. APTI also has a long-term projected growth rate of 12.5%.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
3 Cloud Stocks to Buy Right Now
In a matter of just a few years, “the Cloud” has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. Cloud computing is now an essential focus for software-related companies, and cloud stocks have piqued the interest of many tech-focused investors.
New technologies and changing consumer behavior have changed the shape of the technology landscape, and an industry that was once centered on the personal computer has adapted to survive in the world of mobile computing and the Cloud. The markets have been paying attention, and some of the best tech stocks have been those that are either primarily cloud-based companies, or those that have shown growth in their cloud operations.
With this in mind, we’ve highlighted three stocks that are not only showing strong cloud-related activity, but also strong fundamental metrics. Check out these three cloud stocks to buy right now:
1. Veeva Systems Inc. (VEEV - Free Report)
Veeva makes cloud-based solutions for the pharmaceutical and life sciences industries. Its main offerings are presented in a software-as-a-service model and delivers industry-specific tools for CRM, content management, and many other enterprise applications. Shares of Veeva currently hold a Zacks Rank #2 (Buy).
VEEV has emerged as a hot growth and momentum stock this year, adding more than 64%—even after recent market-wide pullbacks—amid strong earnings improvements. The firm is projected to finish its current fiscal year with earnings growth of 59.1% and has a long-term expected growth rate of 19.3%. Veeva is also generating cash flow growth in excess of 86.6% currently.
2. Attunity Ltd.
Attunity is a provider of software solutions that enable access, management, sharing, and distribution of data across enterprise platforms and the Cloud. Simply put, Attunity customers have real-time access to a plethora of data and information whenever it’s needed. The firm works closely with trusted cloud leaders like AWS, Cloudera , and Microsoft (MSFT - Free Report) .
ATTU is sporting a Zacks Rank #1 (Strong Buy). The reason for this strong rank is a number of recent positive earnings estimate revisions. These bullish revisions have pushed the Zacks Consensus Estimate for ATTU’s current year EPS to 40 cents from 26 cents, while next year’s consensus has moved to 49 cents from 32 cents.
Part of this has to do with Attunity’s most recent quarter, in which the firm delivered earnings of 20 cents per share against estimates of just three cents. Now, current-year growth estimates are calling for revenue and earnings to improve by 35% and 500%, respectively.
3. Apptio, Inc.
Apptio develops cloud-based, software-as-a-service platforms for business management applications. Its enterprise-focused apps are designed to help companies assess and plan for the costs of IT services, which helps save time and money related to planning, budgeting, and forecasting. APTI currently has a Zacks Rank #2 (Buy) and an “A” grade in the Growth category of our Style Scores system.
Despite being a segment leader for years, APTI is still witnessing aggressive earnings and revenue growth. The firm’s bottom line is expected to grow 133.3% this year and revenue growth will hit 24.1%, according to our latest Zacks Consensus Estimates. APTI also has a long-term projected growth rate of 12.5%.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>